Hindpaw inflammation induces tyrosine phosphorylation (tyr-P) of the NMDA receptor (NMDAR) 2B (NR2B) subunit in the rat spinal dorsal horn that is closely related to the initiation and development of hyperalgesia. Here, we show that in rats with Freund's adjuvantinduced inflammation, the increased dorsal horn NR2B tyr-P is blocked by group I metabotropic glutamate receptor (mGluR) antagonists 
Introduction
Glutamate receptors (GluRs) are prominently involved in activitydependent synaptic plasticity that may underlie the mechanisms of learning and memory and persistent pain (Malenka and Nicoll, 1999; Ren and Dubner, 1999; Woolf and Salter, 2000; Ji and Woolf, 2001) . The NMDA receptor (NMDAR), a subtype of ionotropic glutamate receptors, in particular, is activated after injury and contributes to the development of spinal hyperexcitability and hyperalgesia (Haley et al., 1990; Woolf and Thompson, 1991; Dubner and Ruda, 1992) . Recent studies suggest that injury-induced NMDAR activation involves tyrosine phosphorylation (tyr-P) of the NMDA receptor 2B (NR2B) subunit in the spinal dorsal horn (Guo et al., 2002a) . Importantly, the increased NR2B tyr-P depends on primary afferent drive and is closely related to the development of inflammatory hyperalgesia (Guo et al., 2002a) . However, the signal transduction pathways upstream to inflammation-induced NR2B tyr-P are unclear.
The interaction between the NMDAR and metabotropic GluRs (mGluRs) has received increased attention as a mechanism of modulation. Interestingly, NMDARs are physically linked to mGluRs in the postsynaptic density. The group I mGluRs bind Homer protein, and the latter binds Shank, a family of postsynaptic proteins . Shank also is linked to PSD-95 (postsynaptic density-95) via binding with GKAP (guanylate kinaseassociated protein) . Activation of mGluR potentiates NMDA current in dissociated rat spinal dorsal horn neurons (Cerne and Randic, 1992) , Xenopus oocytes Skeberdis et al., 2001) , CA3 pyramidal cells (Benquet et al., 2002) , and NMDAR-mediated synaptic transmission in rat dentate gyrus (O'Connor et al., 1994) . Selective activation of mGluR1 increases NR2 subunit tyr-P in cortical neurons in vitro from mouse (Heidinger et al., 2002) . The possible linkage of NMDAR (and NR2B phosphorylation in particular) and mGluR in the postsynaptic density in the spinal cord and their role in synaptic function are yet to be defined. In addition, the importance of mGluR-NMDAR coupling in an intact in vivo behavioral model of activity-dependent plasticity has not been demonstrated.
Group I mGluRs have been implicated in a variety of pain conditions associated with inflammation, neuropathy, and spinal injury (Meller et al., 1993; Mills et al., 2000; Karim et al., 2001; Walker et al., 2001; Dolan and Nolan, 2002; Hudson et al., 2002; Neugebauer, 2002; Zhang et al., 2002) . The mGluR agonistevoked response is enhanced in the spinal cord from hyperalgesic but not naive animals, and this effect is reversed by an NMDAR antagonist (Boxall et al., 1998) . To test the hypothesis that mGluR-NMDAR coupling plays a role in dorsal horn hyperexcitability, we examined the upstream signaling pathways leading to NR2B tyr-P in the spinal dorsal horn in an in vivo model of inflammation as well as with in vitro methodology. The findings indicate that the ionotropic function of the NMDAR in vivo is subject to phosphorylation regulation that is initiated by mGluR/ G-protein-linked mechanisms during injury-induced spinal dorsal horn plasticity. We further show that the inflammation-and mGluR agonist-induced NR2B tyr-P share similar mechanisms because they both require PKC, intracellular calcium release, and Src activation.
Materials and Methods
Animals. Adult male Sprague Dawley rats weighing 150 -250 gm (Harlan, Indianapolis, IN) were used in all experiments. Rats were on a 12 hr light/dark cycle and received food and water ad libitum. To produce inflammation and hyperalgesia, complete Freund's adjuvant (CFA) (0.05-0.3 ml, 0.1 mg of Mycobacterium tuberculosis; Sigma, St. Louis, MO) suspended in an oil:saline (1:1) emulsion was injected subcutaneously into one or two hindpaws. The CFA injection produced an intense tissue inflammation of the hindpaw characterized by erythema, edema, and hyperalgesia (Iadarola et al., 1988; Hylden et al., 1989; Ren et al., 1992) . The inflamed animals groom normally and display normal locomotor activity. They maintain their weight, explore their environment, and interact with other rats. Naive rats were used as a control. The experiments were approved by the Institutional Animal Care and Use Committee of the University of Maryland Dental School.
Spinal cord slice. Normal adult male Sprague Dawley rats weighing 150 -200 gm (Harlan) were anesthetized with 2% halothane and decapitated. The lumbar spinal cord was removed quickly and kept in the cold artificial CSF (ACSF) consisting of the following (in mM): 124 NaCl, 4.4 KCl, 25 NaHCO 3 , 2.0 CaCl 2 , 1.0 MgSO 4 , 1.0 NaH 2 PO 4 , 10 D-glucose, pH 7.4, and bubbled with 95% O 2 and 5% CO 2 . Transverse spinal cord slices (600 m thick) were cut at 4°C using a vibratome and immersed in chambers perfused at 5 ml/min with oxygenated ACSF. The slices were treated at room temperature with different drugs (see Results) to test their effect on NR2B tyr-P. At the conclusion of pharmacological treatment, the slices were homogenized to extract proteins for immunoprecipitation and Western blot analysis. In the inositol 1,4,5-triphosphate (IP 3 ) challenge experiment, the cellular membrane was permeabilized by a brief (10 sec) application of saponin (0.001%; Calbiochem, La Jolla, CA) to allow penetration of IP 3 through the cell membrane (Solovyova and Verkhratsky, 2003) .
Western blot and immunoprecipitation. Naive and treated rats (10 min to 14 d after CFA injection) were overdosed with pentobarbital sodium (100 mg/kg, i.p.). The dorsal half of the L4 -5 spinal cord tissues was removed and homogenized in solubilization buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 1 mM Na 3 VO 4 , 1 U/ml aprotinin, 20 g/ml leupetin, 20 g/ml pepstatin A). The homogenate was centrifuged at 20,200 ϫ g for 10 min at 4°C, and then the supernatant was removed. The protein concentration was determined using a detergent-compatible protein assay with a bovine serum albumin standard. Each sample contained proteins from one animal. The unresolved proteins left in the pellet were verified, which included Ͻ20% of the total NR2B proteins (data not shown).
For Western blot analysis, the proteins (50 g) were separated on a 7.5% SDS-PAGE gel and blotted to nitrocellulose membrane (Amersham Biosciences, Arlington Heights, IL) with a Trans-Blot Transfer Cell system (Bio-Rad, Hercules, CA). The blots were blocked with 5% milk in TBS buffer (20 mM Tris, 150 mM NaCl, pH 7.4) at room temperature for 30 min. After decanting the blocking buffer, the blot was incubated with the respective antibody overnight at 4°C. The membrane was washed with TBS buffer and incubated for 1 hr with anti-goat IgG horseradish peroxidase (HRP) (1:3000; Santa Cruz Biotechnology, Santa Cruz, CA) in 5% milk/TBS. The membrane was then washed three times with TBS buffer. The immunoreactivity was detected using enhanced chemiluminescence (ECL) (Amersham Biosciences). The loading and blotting of equal amount of proteins were verified by reprobing the membrane with anti-␤-actin antiserum (Sigma) and with Coomassie blue staining.
For immunoprecipitation, the samples were incubated with respective antiserum overnight and then with protein A/G-Sepharose beads (Santa Cruz Biotechnology). SDS sample buffer (0.05 ml) was added to elute proteins from the protein A/G beads. The eluant was separated on SDSpolyacrylamide gel (7.5%) and transferred to a nitrocellulose membrane. To determine the level of tyr-P, the membranes were blocked and incubated with anti-phosphotyrosine 4G-10 (1:1000; Upstate Biotechnology, Charlottesville, VA) and further washed and incubated with anti-mouse IgG HRP (1:3000), and ECL was performed. The membranes were then stripped and reprobed with NR2B antiserum (1:1000). The specificity of immunoprecipitation was verified by boiling the sample before IP, thus breaking the protein-protein complex and only immunoprecipitating the target protein (Guo et al., 2002) . After incubation with 4G-10, the eluted NR2B protein sample exhibited a band of 180 kDa that is the expected size for tyrosine-phosphorylated NR2B proteins. In the remaining sample that is deprived of NR2B, no specific band was identified at the 180 kDa position after incubation with 4G-10 and anti-NR2B antibodies (data not shown).
For co-immunoprecipitation of proteins associated with the NMDAR complex, the membranes were repeatedly stripped and probed with Shank (1:5000), NR2B (1:500 -1000), PSD-95 (1:10,000), and Src (1:200) antibodies. GluR1 (1:500) antibody was used as a control. A set of samples was boiled for 5 min before immunoprecipitation to separate the protein complex and verify the specificity of antibodies.
The ECL-exposed films were digitized, and densitometric quantification of immunoreactive bands was performed using Scion (Frederick, MD) NIH Image 1.63. The relative tyrosine-phosphorylated protein levels were obtained by comparing the anti-phosphotyrosine immunoblot against the corresponding NR2B subunit immunoblot from the same membrane, and the deduced ratios were further normalized to that of the naive rats. This procedure avoids the variability resulting from the difference in film exposure. Data are illustrated as percentage of the naive controls. Raw data (ratio of the 4G-10 band over NR2B band) were used for statistical comparisons. ANOVA and the unpaired two-tailed t test were used to determine significant differences between sample groups. p Ͻ 0.05 was considered significant in all cases.
Immunocytochemistry. Rats were deeply anesthetized with pentobarbital and perfused transcardially with 100 ml of saline followed by 500 ml of cold (4°C) 0.1 M phosphate buffer containing 4% paraformaldehyde. The L4,5 spinal cord was removed, immersed in the same fixative overnight at 4°C, and transferred to 30% sucrose (w/v) in phosphate buffer for several days for cryoprotection. Thirty micrometer-thick sections were cut with a cryostat at Ϫ20°C. Free-floating tissue sections were incubated with rabbit anti-Shank (1:5000) or mouse anti-Src monoclonal antibodies (1:2000; Chemicon, Temecula, CA) overnight. The sections were then incubated with biotinylated goat anti-rabbit IgG or goat anti-mouse IgG (1:400; Vector Laboratories, Burlingame, CA) followed by indocarbocyanine (Cy3)-conjugated Streptavidin (1:600; Jackson ImmunoResearch, West Grove, PA). Control sections were processed with the same method except that the primary antisera was omitted or adsorbed by respective antigens.
Tyramide signal amplification (TSA) was used for doubleimmunofluorescent staining (Shindler and Roth, 1996; Burette et al., 1999) . After overnight incubation with the first primary antibody, rabbit anti-NR1 (1:10,000; Upstate Biotechnology), sections were reacted for 2 hr at room temperature with biotinylated secondary antibody (1:400; Jackson ImmunoResearch) followed by incubation with Streptavidinperoxidase for 1 hr. After the application of Cy3-tyramide (PerkinElmer Life Sciences, Boston, MA), sections were washed with PBS and incubated in 4 M UREA (carbamide; in distilled water; Sigma) for 15 min. The treatment with the denaturing reagent removes the primary-secondary complex, whereas the tyramide fluorescein marker deposited on the tissue remains. The sections were then incubated with the second primary antibody, rabbit anti-mGluR5 (1:500; Upstate Biotechnology), and visualized by goat anti-rabbit IgG conjugated to Alexa Fluor 488 (1:600; Molecular Probes, Eugene, OR). After washes in PBS, sections were mounted on gelatin-coated slides and coverslipped with Vectashield (Vector Laboratories). To control for cross-reactions between the two primary antibodies, some sections were processed as above except that the second primary antibody was omitted. These sections showed normal Cy3-TSA (red) labeling but were negative on the green channel (Alexa 488). Images were collected sequentially on the Bio-Rad (LaserSharp 2000) or Zeiss (Thornwood, NY) 510 MATA laser-scanning confocal microscope.
Intrathecal procedure. The intrathecal (i.t.) cannulation was performed under methohexital anesthesia (50 mg/kg, i.p.). The atlanto-occipital membrane was exposed, and a 7-8 cm length of PE-10 tubing was inserted into the subarachnoid space through a slit made in the membrane. The cannula was advanced to the level of the lumbar spinal cord (Yaksh and Rudy, 1976) . After recovery from anesthesia, animals were examined for gross signs of motor impairment. Such animals were excluded from the study. The location of the distal end of the i.t. catheter was verified visually after laminectomy at the end of the experiments. Each drug was injected in a volume of 5-10 l followed by a flush of 10 l of saline.
Drugs and agents. The following agents were purchased from Tocris Cookson (Ellisville, MO): [(1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) -3,5-pyridinedicarboxylic acid 2-methyloxyethyl 1-methylethyl ester], and -conotoxin MVIIC (nonselective VDCC blocker). The following agents were purchased from Sigma-RBI (Natick, MA): NMDA receptor channel blocker (5R,10S)-(ϩ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801), NMDA receptor channel blocker ketamine hydrochloride (ketamine), and AMPA/kainate (KA) receptor antagonist 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfonamide disodium (NBQX). The following agents were purchased from Calbiochem: 2-Aminoethoxydiphenylborate (2APB; inhibitor of IP 3 -mediated calcium release), mitogen-activated protein kinase kinase (MAPKK/MEK) inhibitor 2Ј-amino-3Ј-methoxyflavone (PD98059), PKC activator phorbol-12-myristate-13-acetate (PMA), 4␣-Phorbol-12,13-didecanoate (4␣PDD; inactive analog of PMA), chelerythrine chloride (PKC inhibitor), IP 3 receptor activator D-IP 3 (D-myo-inositol 1,4,5-trisphosphate, Hexasodium salt), and L-IP 3 (L-myo-inositol 1,4,5-trisphosphate, hexapotassium salt; inactive analog of D-IP 3 ). CGP 77675 (Src family protein tyrosine kinase inhibitor) was a gift from Novartis (Basel, Switzerland). The drugs were dissolved in saline or dimethylsulfoxide (DMSO) (Sigma), and the drug vehicle was used as a control. The doses of all agents were selected based on previous use in relevant studies.
The following antibodies were purchased: NR2B (Santa Cruz Biotechnology); 4G-10, PSD-95, Src, NR1, and mGluR5 (Upstate Biotechnology); and GluR1 (Chemicon). Shank antibodies were raised in rabbits immunized with GST fusions of Shank3 residues 1379 -1740 and 1379 -1675 .
Behavioral testing. A unilateral hindpaw inflammation was produced. Complete Freund's adjuvant (0.05 ml) suspended in an oil/saline (1:1) emulsion was injected subcutaneously into the lateral edge of one hindpaw. A set of calibrated Semmes-Weinstein monofilaments (von Frey filaments; Stoelting, Wood Dale, IL) was used to deliver mechanical stimulation. The bending force of the filaments was in a range of 9 mg to 257 gm. The testing method has been described in detail previously (Ren, 1999) . Briefly, rats were habituated to stand on their hindpaws and lean against the experimenter's hand covered by a regular leather work glove. The testing filament was probed against the lateral edge of the hindpaw. The filaments were applied in an ascending series. A descending series of the filaments were used when the rat responded to the starting filament. Each filament was tested five times at an interval of a few seconds. If paw withdrawal resulting from stimulation was observed, it was registered as a response to a filament. The response frequencies [(number of responses/number of stimuli) ϫ 100%] to a range of von Frey filament forces were determined, and a stimulus-response frequency curve was plotted. After a nonlinear regression analysis, an EF 50 value, defined as the von Frey filament force ( g ) that produces a 50% response frequency, was derived from the stimulus-response function curve. The EF 50 values were used as a measure of mechanical sensitivity. A cutoff value of the EF 50 was set at 118 gm for the noninflamed paw because the responses were limited to a few high-intensity filaments with large force intervals. A reduction in EF 50 suggests the development of mechanical allodynia, a nociceptive response to a normally non-noxious stimulus. An increase in response frequency, particularly to suprathreshold von Frey filaments, indicates mechanical hyperalgesia. ANOVA with repeated measures and post hoc comparisons were performed for statistical analysis. p Ͻ 0.05 was considered statistically significant.
Results

Inflammation induces NR2B tyrosine phosphorylation
We have shown previously that there was a rapid and prolonged increase in tyr-P, but not the protein levels, of the NR2B subunit in the spinal dorsal horn after hindpaw inflammation (Guo et al., 2002a) . The increase in NR2B tyr-P was dependent on primary afferent drive because of the following: (1) the phosphorylation correlated with the temporal profile of inflammation and hyperalgesia, (2) shorter duration noxious stimulation produced a rapid and shorter-lasting increase in phosphorylation, and (3) local anesthetic block of the injected paw reversibly blocked inflammation-induced NR2B tyr-P and delayed hyperalgesia. In addition, intrathecal administration of an Src family tyrosine kinase inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), delayed the onset of hyperalgesia (Guo et al., 2002a) . Thus, the increase in NR2B tyr-P correlated closely with the development of inflammation and hyperalgesia.
We use this in vivo model to examine the mechanisms of the enhanced NR2B tyr-P. The enhanced NR2B tyr-P is site specific. Comparing the effects of CFA injection on the contralateral versus ipsilateral spinal cord, we observed that at 24 hr after CFA injection, NR2B tyr-P was selectively increased in the ipsilateral spinal dorsal horn (Fig. 1) . The levels of NR2B tyr-P were not affected in the contralateral lumbar spinal dorsal horn or cervical spinal cord from the same animal. Injection of saline into the hindpaw did not induce a change in tyr-P at 24 hr after injection. These findings control for the concern that NR2B phosphorylation might be attributable to nonspecific effects of stress on the animal. In the following experiments, we have expanded these findings to identify the signaling pathways involved in inflammation-induced NR2B tyr-P by using a series of receptor agonists and antagonists and kinase activator and inhibitors in both in vivo and in vitro preparations. mGluR activation and NR2B tyrosine phosphorylation Group I mGluRs have been implicated in a variety of pain conditions (Meller et al., 1993; Karim et al., 2001; Dolan and Nolan, 2002; Neugebauer, 2002; Zhang et al., 2002) . To determine whether mGluR activation is involved in inflammation-induced NR2B tyr-P, we first examined the effect of selective group I mGluR receptor antagonists in vivo. An mGluR1-selective antagonist, CPCCOEt (2.0 mol; n ϭ 6), or mGluR5-selective antagonist, MPEP (170 nmol; n ϭ 4), was injected intrathecally at 10 min before injection of CFA. The rats were killed at 30 min after injection of CFA, when the NR2B tyr-P reaches maximum levels (Guo et al., 2002a) . Compared with the vehicle control (DMSO; 0.01 ml), the inflammation-induced NR2B tyr-P was abolished by pretreatment with CPCCOEt and MPEP (Fig. 2 A) . The basal levels of NR2B tyr-P were not affected by the same doses of CPCCOEt and MPEP (Fig. 2C) . These results suggest a linkage between group I mGluR activation and inflammation-induced NR2B tyr-P.
Signal transduction cascade between mGluR activation and NR2B tyrosine phosphorylation
The signal pathways immediately upstream to NMDAR tyr-P involve the Src family protein tyrosine kinases (Yu et al., 1997) . We have shown that inflammation-induced dorsal horn NR2B tyr-P is blocked by genistein, a nonselective tyrosine kinase inhibitor, and PP2, a selective Src family tyrosine kinase inhibitor (Guo et al., 2002a) . In the present study, the involvement of Src was further examined by a potent Src inhibitor, CGP 77675. The pretreatment of CGP 77675 significantly reduced CFA-induced NR2B tyr-P in vivo (100 pmol; n ϭ 5; p Ͻ 0.05) (Fig. 2 B, left) . The basal levels of NR2B tyr-P were not affected by the same dose of CGP 77675 (Fig. 2C) . Interestingly, PD98059 (4.0 nmol; n ϭ 6; i.t.), a MAPKK/MEK inhibitor, did not block inflammationinduced NR2B tyr-P (Fig. 2 B, right) , although the dose used had been shown to inhibit spinal ERK (extracellular signal-regulated kinase) activation and nociception (Ji et al., 1999) . The above results suggest a sequence of events, including mGluR and Src activation and eventual NR2B tyr-P. The activity of MAP kinase, in contrast, may represent a down stream, or a parallel signaling pathway, to inflammation-induced dorsal horn NR2B tyr-P.
The Src family tyrosine kinases are activated by the prolinerich tyrosine kinase 2 (Pyk2)/cell-adhesion kinase ␤ pathway (Dikic et al., 1996; Huang et al., 2001 ). PKC activation is also required for inflammation-induced NR2B tyr-P (Guo et al., 2002a) . Both Pyk2 and PKC activation require an increase in intracellular calcium. One logical hypothesis is that calcium is mobilized from intracellular stores through the activation of the IP 3 pathway following mGluR activation. We directly tested this hypothesis with the administration of IP 3 receptor antagonists. As shown in Figure 3A , intrathecal pretreatment of 2APB (1.0 nmol; n ϭ 6), a membrane permeable IP 3 receptor antagonist that does not affect Ca 2ϩ release from the ryanodine-sensitive Ca 2ϩ stores (Maruyama et al., 1997) , blocked NR2B tyr-P after inflammation. The basal levels of NR2B tyr-P were not affected by the same doses of 2APB (Fig. 2C ).
An increase in intracellular calcium can also be a result of an inflow of extracellular calcium through calcium-permeable channels. Because Src may mainly regulate the activity of already active NMDAR channels (Salter, 1998) , we next examined the possibility that enhanced tyr-P is a feedforward regulatory mechanism triggered by inflammation-induced NMDAR activation and associated calcium influx. An NMDAR channel blocker, MK-801 (60 nmol; n ϭ 4), was administered intrathecally 10 min before injection of CFA, the same procedure we used to block spinal NMDAR activation (Ren et al., 1992) . The result showed that the increased NR2B tyr-P was not affected by MK-801 pretreatment (Fig. 3B, left) . Intrathecal administration of ketamine (180 nmol; n ϭ 5), an alternative NMDAR channel blocker, also did not reverse inflammation-induced increase in NR2B subunit tyr-P (data not shown). The AMPA/KA receptor channels are other potential sources of calcium for intracellular signaling, because calcium-permeable AMPA receptors exist in the superficial dorsal horn (Engelman et al., 1999) . We have shown that intrathecal injection of 1.3-13 nmol of NBQX dose-dependently attenuated CFA-induced hyperalgesia (Guo et al., 2002b) . However, NBQX (13 nmol; n ϭ 3), an AMPA/KA receptor antagonist, did not affect CFA-induced NR2B tyr-P (Fig. 3B, right) .
In an additional experiment, we examined the possible involvement of VDCCs in increased NR2B tyr-P. -conotoxin GVIA (1.3 nmol; n ϭ 3; an N-type VDCC blocker), NIMO (120 nmol; n ϭ 3; an L-type VDCC blocker), or -conotoxin MVIIC (100 nmol; n ϭ 4; a nonselective VDCC blocker) were injected intrathecally 10 min before injection of CFA. DMSO (0.01 ml) was used as a vehicle control. As shown in Figure 3C , the mean levels of tyrosine-phosphorylated NR2B proteins were not affected by the VDCC blockers. We verified the effectiveness of the VDCC blocker treatment. Consistent with the literature (Malmberg and Yaksh, 1994; Matthews and Dickenson, 2001) , intrathecal administration of nimodipine (120 nmol; n ϭ 4), -conotoxin GVIA (1.3 nmol; n ϭ 4), and -conotoxin MVIIC (100 nmol; n ϭ 4) produced a reduction of inflammatory hyperalgesia (data not shown). Because -conotoxins also block a significant amount of low-voltage-activated calcium channels (LVACC currents) (McCallum et al., 2003) , a role for LVACC in this effect seems unlikely. These results suggest that intracellular Figure 1 . Selective increase in NR2B tyr-P after hindpaw inflammation. Proteins were extracted from L4,5 spinal cord of noninflamed naive (N) rats and rats at 24 hr after complete Freund's adjuvant or saline injection. The spinal dorsal horn was divided at the midline into the ipsilateral (ipsi) and contralateral (Con) halves. Cervical spinal cord (Cer) was used as a control. The top blot shows the immunoreactive bands against anti-phosphotyrosine 4G-10 (PY-NR2B) after immunoprecipitation of extracted proteins with anti-NR2B antibodies. The bottom blot shows immunobands against NR2B antibodies after stripping and reprobing the same membrane previously probed with 4G-10 antibodies. The levels of tyr-P were normalized to the respective NR2B immunoreactive bands. The relative phosphotyrosine protein levels (mean Ϯ SEM) are expressed as a percentage of the naive controls for the purpose of illustration. Raw data were used for statistical comparisons. The asterisks indicate significant differences ( p Ͻ 0.05) from the naive controls. n ϭ 5 per time point. The dashed line indicates the control levels in noninflamed rats.
calcium mobilization but not influx through calcium-permeable channels plays a key role in inflammation-induced NR2B tyr-P.
mGluR activation in vitro induces NR2B tyrosine phosphorylation
The involvement of mGluR in NR2B tyr-P was next studied in an in vitro slice preparation by agonist challenge. Dorsal spinal cord slices were obtained from adult Sprague Dawley rats. After a 15 min incubation of the slice with DHPG (100 M; n ϭ 10), a selective group I mGluR agonist, an increase in NR2B tyr-P was observed when compared with the vehicle-treated slice ( p Ͻ 0.05) (Fig. 4 A) . Incubation of the spinal slice with APDC (100 M; n ϭ 6), a group II mGluR agonist, or L-AP-4 (100 M; n ϭ 6), a group III mGluR agonist, did not produce a significant increase in NR2B tyr-P (Fig. 4 A) . The DHPG-induced increase in NR2B tyr-P in the spinal slice was blocked by a 10 min pretreatment with CPCCOEt (100 M; n ϭ 6) or MPEP (10 M; n ϭ 6) (Fig.  4 B) . The DHPG-induced in vitro NR2B tyr-P was also blocked by CGP 77675 (10 M; n ϭ 6) (Fig. 4C, left) , a PKC inhibitor, chelerythrine (10 M; n ϭ 4) (Fig. 4C, middle) , and 2APB (72 M; n ϭ 6) (Fig. 4C, right) . The basal levels of NR2B tyr-P in the spinal slice were not affected by the same doses of chelerythrine, CGP 77675, CPCCOEt, MPEP, and 2APB (Fig. 4 D) . These results further suggest that group I mGluR activation is linked to NR2B tyr-P.
Agonist challenge with an IP 3 receptor agonist and PKC activation
The above findings suggest that the activation of the IP 3 pathway is necessary to induce NR2B tyr-P. This hypothesis was next tested by directly applying IP 3 receptor agonists to the spinal slice preparation. The permeabilization method was used to allow IP 3 to penetrate the cell membrane (Solovyova and Verkhratsky, 2003) . The spinal slice was incubated with D-IP 3 (100 M; n ϭ 4), an IP 3 receptor activator, and L-IP 3 (100 M; n ϭ 4), an inactive analog of D-IP 3 for 15 min, and the tissues were used for immunoprecipitation and Western blot analysis. D-IP 3 induced a significant increase in NR2B tyr-P compared with the untreated (naive) slice ( p Ͻ 0.05), whereas L-IP 3 did not produce a significant effect (Fig. 5A ). The IP 3 -induced increase in tyr-P was blocked by pretreatment with the Src inhibitor CGP 77675 (10 M; n ϭ 4) (Fig. 5A) . We then verified whether the direct activation of PKC, a downstream event to IP 3 -mediated intracellular release, could also mimic CFA-induced NR2B tyr-P. Compared with an inactive analog 4␣PDD (10 M; n ϭ 5), PMA (1-10 M; n ϭ 5) produced a significant increase in NR2B tyr-P in the spinal slice ( p Ͻ 0.05) (Fig. 5B) . The PMA-induced NR2B tyr-P was blocked by pretreatment of the slice with CGP 77675 (10 M; n ϭ 5) and a PKC inhibitor, chelerythrine (10 M; n ϭ 5) (Fig. 5B) . Statistical comparisons were made among all groups using raw data. *p Ͻ 0.05 versus naive rats. A, The effect of CPCCOEt (2 mol; n ϭ 6; left), an mGluR1 antagonist, and MPEP (170 nmol; n ϭ 4; right), a mGluR5 antagonist. B, The inflammation-induced NR2B tyr-P requires Src activity. The NR2B tyr-P was blocked by intrathecal pretreatment of CGP 77675 (100 pmol; n ϭ 5), an Src family protein tyrosine kinase inhibitor (left). PD98059 (4 nmol; n ϭ 6; i.t.), a MAPKK inhibitor, did not prevent NR2B tyr-P after inflammation (right). C, The basal levels of NR2B tyr-P in naive rats were not affected by the same dose of CGP 77675, CPCCOEt, MPEP, and 2APB compared with vehicle (VEH)-treated rats (n ϭ 2).
These results further establish that activation of the IP 3 -PKC pathway is sufficient to induce spinal dorsal horn NR2B tyr-P.
Src, NR2B, PSD-95, and Shank coprecipitate in the spinal dorsal horn
Previous studies suggest a link between mGluRs, NMDARs, and protein tyrosine kinase in the postsynaptic density. Coimmunoprecipitation has demonstrated the ternary or quadruple complex involving Src family protein tyrosine kinase Fyn-NR2A-PSD-95 (Tezuka et al., 1999; Lei et al., 2002) , mGluR-HomerShank-PSD-95 , and Shank-GKAP-PSD-95 ) from human embryonic kidney 293 cells or rat brain. Proteomic characterization of the mouse brain has shown that the NMDAR multiprotein complex contains at least 19 proteins participating in NMDA receptor signaling (Husi et al., 2000) . It is not known whether the Src-NMDAR-PSD-95 complex is directly associated with the mGluRHomer-Shank protein complex in spinal dorsal horn postsynaptic neurons.
To assess the molecular basis of mGluR-NMDAR interaction underlying inflammation-induced NR2B tyr-P, we determined whether the NR2B subunit of the NMDAR is linked to tyrosine kinase and proteins associated with mGluRs in the spinal dorsal horn. Total proteins were extracted from spinal dorsal horn tissues and were coimmunoprecipitated with antibodies recognizing Src, Shank, NR2B, or PSD-95. All four proteins were present in the spinal dorsal horn (Fig. 6, left blots) . Shank was represented as a 210 kDa band followed by NR2B at 180 kDa, PSD-95 at 95 kDa, and Src at 60 kDa.
When antibodies recognizing Src were used to immunoprecipitate, Shank, NR2B, and PSD-95 were also detected in immunoprecipitates after repeated stripping and probing (Fig. 6 , middle blots). Similarly, Shank antibodies coprecipitated NR2B, Src, and PSD-95 (Fig. 6, right blots) . In contrast, GluR1 proteins were not coprecipitated (Fig. 6) . Boiling tissue extracts before immunoprecipitation interrupted the coimmunoprecipitation of associated proteins, leaving only Src or Shank in the immunoprecipitates (Fig. 6 , left two lanes of the middle and right blots). Similar results were obtained when NR2B-selective or PSD-95-selective antibodies were used for immunoprecipitation (data not shown). These results indicate that Shank, a protein closely associated with mGluRs, is also associated with a complex that includes Src protein tyrosine kinase, NR2B, and PSD-95.
The complex involving Src, NR2B, PSD-95, and Shank is likely a postsynaptic structure in intrinsic spinal neurons, because spinal PSD-95 is not present in dorsal root ganglion neurons and is not affected by spinal nerve axotomy and dorsolateral funiculus lesions (Tao et al., 2000) . NR2B and PSD-95 immunoreactivity has been observed in the superficial laminas of the dorsal horn (Boyce et al., 1999; Tao et al., 2000) . The Shank-and Src-like immunoreactivity is also intensely localized to rat spinal dorsal horn neurons (Fig. 7) . Densely stained cell bodies are observed in the superficial (Fig. 7C,C1 , D, D1) and deep (Fig. 7C,C2, D, D2 ) dorsal horn, a key structure in initial nociceptive processing. Numerous ventral horn neurons also exhibited Shank and Src immunoreactivity (Fig. 7 A, B) . Double immunofluorescence studies indicated that NMDAR colocalized with mGluR in dorsal horn neurons (Fig. 8) . Figure  8 A-C shows that in the lateral lamina V of the dorsal horn, many NR1-labeled neurons (red) overlap with mGluR5-positive neurons (green). The NR1 staining often exhibited punctate profiles in the cell membrane, dendrite, and cytoplasm (Fig. 8A 1 ) . The mGluR5-like immunoreactivity, in contrast, appeared uniformly in the cell membrane and cytoplasm (Fig. 8B 1 ) . Immunoprecipitation analysis further indicated that mGluR5 proteins coimmunoprecipitated with NR2B proteins (Fig. 8D) . These results provide anatomical and biochemical evidence that supports the signal coupling of mGluR with NMDAR in the spinal dorsal horn. Contribution of calcium-releasing pathways to NR2B tyr-P. Drugs were injected intrathecally 10 min before CFA injection into the two hindpaws. DMSO (0.01 ml) and saline (0.01 ml) were vehicle controls. Dorsal horn tissues were collected at 30 min after inflammation. A, IP 3 receptor inhibitor 2APB (1.0 nmol; n ϭ 6; right) blocked inflammation-induced NR2B tyr-P. B, Ionotropic glutamate receptor antagonists MK-801 (60 nmol; n ϭ 4; left) and NBQX (13 nmol; n ϭ 3; right) did not block NR2B tyr-P. C, VDCC blockers -conotoxin GVIA (1.3 nmol; n ϭ 3; left), NIMO (120 nmol; n ϭ 3; left), and -conotoxin MVIIC (100 nmol; n ϭ 4; right) did not prevent inflammation-induced NR2B tyr-P. *p Ͻ 0.05 versus naive rats.
Group I mGluR antagonists and IP 3 receptor inhibitor attenuate inflammatory hyperalgesia and allodynia
We next examined whether the antagonism of group I mGluRs and IP 3 receptors affected the initiation and maintenance of inflammatory hyperalgesia. Behavioral hyperalgesia, an exaggerated nocifensive response to a noxious stimulus, and allodynia, pain induced by a normally non-noxious stimulus, develop quickly after hindpaw inflammation (Guo et al., 2002a) . We assessed mechanical hyperalgesia and allodynia of the hindpaw according to the study by Ren (1999) . A series of calibrated von Frey filaments with bending forces ranging from 0.009 to 257 gm were applied to the hindpaw skin surface. An active withdrawal of the paw from the probing filament was defined as a response. Each von Frey filament was applied five times at intervals of a few seconds. The response frequencies to the range of von Frey filament forces were determined, and stimulus-response frequency curves were plotted (Fig. 9A) . This stimulus-response frequency curve represents responses to threshold as well as suprathreshold stimuli and an EF 50 value, defined as the von Frey filament force ( g) that produces a 50% response frequency, can be derived after a nonlinear regression analysis. Before injection of CFA, there was no significant difference between the baseline stimulus-response frequency curves for different groups of animals, indicating consistent responses to von Frey filaments (Fig. 9A, pre-CFA) . After the CFA injection, there was a leftward shift of the curve (Fig. 9A ) (30 min vehicle vs baseline vehicle). The shift of the stimulusresponse frequency function curve after inflammation indicates an increased response to suprathreshold stimuli and a decrease in EF 50 value. These inflammation-induced changes suggest the presence of mechanical hyperalgesia and allodynia, because there was an increase in response to suprathreshold stimuli and a decreased response threshold for nocifensive behavior. Also shown in Figure 9A , pretreatment of two group I mGluR antagonists, CPCCOEt (2 mol) and MPEP (170 nmol), resulted in a rightward shift of the stimulus-response curves (Fig. 9A, 30 min post-CFA), suggesting an almost complete reversal of behavioral hyperalgesia and allodynia. At 2 hr post-CFA, the hyperalgesia and allodynia were partially recovered as indicated by a leftward shift of the stimulus-response curves (Fig. 9A ) (2 hr CPCCOEt/ MPEP vs 30 min CPCCOEt/MPEP).
The effects of mGluR antagonists and an IP 3 receptor inhibitor on mechanical Figure 4 . The mGluR agonists induced NR2B tyr-P in vitro. The transverse spinal cord slice was obtained from adult 8-to 10-week-old rats. Spinal slices were incubated with drugs for 15 min before protein extraction. In all panels, representative immunoblots against anti-4G-10 (PY-NR2B) and anti-NR2B antibodies are shown at the top, and mean relative levels of tyrosinephosphorylated NR2B proteins are shown in the bar graphs. The dashed line in the bar graphs indicates the percentage of naive level. *p Ͻ 0.05 versus naive untreated slices. A, Selective group I (DHPG; 100 M; n ϭ 10) but not group II (APDC; 100 M; n ϭ 6) and group III (L-AP-4; 100 M; n ϭ 6) mGluR agonists induced NR2B tyr-P in spinal slice. DHPG-induced NR2B tyr-P was blocked by CPCCOEt (100 M; n ϭ 6) and MPEP (10 M; n ϭ 6) ( B), an Src inhibitor, CGP 77675 (CGP; 10 M; n ϭ 6) (C, left), a PKC inhibitor, chelerythrine (Che; 10 M; n ϭ 4) (C, middle), and an IP 3 receptor inhibitor 2APB (72 M; n ϭ 6) (C, right). D, The basal levels of NR2B tyr-P in naive rats were not affected by the same dose of Che, CGP 77675, CPCCOEt, MPEP, and 2APB compared with vehicle (VEH)-treated rats (n ϭ 2).
hyperalgesia and allodynia were quantified by comparing the EF 50 values (Fig. 9 B, C) . In pretreatment experiments, the EF 50 values of the inflamed paw were significantly increased in CPCCOEt-treated (2 mol; n ϭ 5), MPEP-treated (170 nmol; n ϭ 5), or 2APB-treated (1 nmol; n ϭ 6) rats to pre-CFA levels at 1-30 min after inflammation when compared with vehicletreated rats and to pre-CFA controls (Fig. 9B) . At 2 hr time points, the EF 50 values did not show a significant difference from the vehicle-injected rats, although they appeared to remain at an elevated level. In post-treatment experiments, mechanical hyperalgesia-allodynia was determined at 1 d after CFA injection and then CPCCOEt (2 mol; n ϭ 4), MPEP (170 nmol; n ϭ 5), or 2APB (1 nmol; n ϭ 6) were intrathecally injected. The posttreatment with CPCCOEt and MPEP produced a slight increase in EF 50 values of the inflamed paw that lasted for ϳ5 min (Fig.  9C) . The post-treatment with 2APB did not produce an effect on hyperalgesia. Thus, compared with pretreatment, the posttreatment of mGluR antagonists appeared to be less effective in reversing inflammatory hyperalgesia. There was no effect of the mGluR antagonists on mechanical responses of the contralateral noninflamed paw in either pretreatment or post-treatment paradigm ( Fig. 9 B, C) . These results suggest that the activation of the group I mGluRs is important for the initiation but plays less of a role in the maintenance of inflammatory hyperalgesia.
Discussion
The present study addresses signal pathways that mediate in vivo NR2B tyr-P in the spinal dorsal horn in a model of inflammation and hyperalgesia. We extend previous findings by showing that administration of selective group I mGluR antagonists completely blocks NR2B tyr-P as well as mechanical hyperalgesia and allodynia after inflammation. In addition, in an in vitro spinal dorsal horn slice preparation, application of group I mGluR agonists produces NR2B tyr-P that mimics the CFA-induced in vivo effect. Importantly, additional analysis in both the in vivo inflammatory hyperalgesia model and the in vitro model indicate that IP 3 receptor-mediated intracellular calcium release and Src family kinases play a critical role in triggering the cascade that leads to NR2B tyr-P. These findings suggest that the activation of mGluRs is key to initiating an enhanced NMDAR response after tissue injury. Thus, the ionotropic function of the NMDAR in vivo is subject to tyr-P regulation that is initiated by mGluR/G-proteinlinked mechanisms during inflammation-induced spinal dorsal horn plasticity. The hypothesis that the induction of spinal dorsal horn sensitization after inflammation is related primarily to activity of NMDA, AMPA, NK-1, and Trk B receptors (Woolf and Salter, 2000; Hunt and Mantyh, 2001) needs to be revised in light of the present findings.
The spinal dorsal horn is the major site for initial nociceptive processing. Our coimmunoprecipitation experiments suggest that in the dorsal horn, mGluR-Homer-Shank complex and NMDARs are biochemically linked through related postsynaptic density proteins such as PSD-95 and Shank. In addition, this super protein complex also includes Src family protein tyrosine kinases (Tezuka et al., 1999; Lei et al., 2002; our results) that are important modulators of NMDAR channels (Yu et al., 1997) . Accordingly, the NR2B subunit may be phosphorylated by kinases intrinsic to this protein complex. The mGluR-NMDAR coupling in dorsal horn neurons is supported by the fact that selective mGluR antagonists block inflammation-induced NR2B tyr-P and selective mGluR agonist-induced NR2B tyr-P in spinal slices. Previous studies have shown that activation of group I mGluRs enhances NMDA-induced currents (Cerne and Randic, Figure 5 . IP 3 and PMA induced NR2B tyr-P in vitro. A, D-IP 3 (100 M; n ϭ 4), an IP 3 receptor activator, induced a significant increase in NR2B tyr-P compared with untreated (naive) slices. The increased NR2B tyr-P was blocked by pretreatment with CGP 77675 (10 M; n ϭ 4). L-IP 3 (100 M; n ϭ 4), an inactive analog of D-IP 3 , did not produce a significant effect. The slices were permeabilized by exposure to a brief (10 sec) application of saponin (0.001%) to allow penetration of IP 3 through cell membrane. Saponin itself [saponin plus vehicle (Veh)] did not affect the level of NR2B tyr-P. B, Direct application of PMA to spinal slices to activate PKC, a downstream event to IP 3 -mediated intracellular release, also mimicked CFA-induced NR2B tyr-P. PMA (1 M; n ϭ 5) produced a significant increase in NR2B tyr-P in the spinal slice. The inactive analog 4␣PDD (10 M; n ϭ 5) did not produce a significant effect. The PMA-induced NR2B tyr-P was blocked by inhibitors of Src (CGP 77675, 10 M) and PKC [chelerythrine (Che)]. *p Ͻ 0.05 versus naive untreated slices.
1992; Bond and Lodge, 1995) and the NMDA-mediated increase in intracellular calcium concentration in dorsal horn neurons (Bleakman et al., 1992) . A role of mGluR in central sensitization and persistent pain has been suggested previously (Morisset and Nagy, 1996; Neugebauer et al., 1999; Karim et al., 2001) . The present study further shows that the effects of mGluR agonists are coupled to NR2B phosphorylation and that the inflammation-and mGluR agonist-induced NR2B tyr-P share similar mechanisms, because they both require PKC (Guo et al., 2002a) , intracellular calcium release, and Src activation.
It is known that activation of group I mGluRs produces nocifensive behaviors in rats (Lorrain et al., 2002) , although the mechanisms of these effects were unclear. A number of studies have indicated a role of group I mGluRs in central sensitization and hyperalgesia (Fisher and Coderre, 1996; Neugebauer et al., 1999; Karim et al., 2001) . In the present study, the pretreatment of mGluR1 or mGluR5 antagonists significantly delayed the development of mechanical hyperalgesia and allodynia after inflammation. Similar to the effect of the NMDAR antagonist (Ren et al., 1992) , the group I mGluR antagonists did not produce an effect on the noninflamed paw, suggesting a selective effect on hyperalgesia. Intrathecal administration of the IP 3 receptor antagonist also produced a similar effect. Importantly, the same dose of these mGluR antagonists selectively blocked inflammation-induced, but not basal levels of, NR2B tyr-P. Our results also suggest that the postsynaptic mGluR-NMDAR coupling after inflammation mainly occurs in the initiation phase of dorsal horn hyperexcitability, because the posttreatment of the mGluR antagonists only produced a minor effect. Other signaling pathways may be more important for the maintenance of persistent sensitization. It was noted in the present study that antagonists of mGluR1 and mGluR5 each individually blocked NR2B tyr-P and attenuated behavioral hyperalgesia. Although these results suggest that the involvement of both group I mGluR subtypes is necessary in coupling NMDAR signaling, the molecular mechanisms underlying this phenomenon is unclear. One attractive speculation related to these results is the oligomerization of the mGluRs. G-protein-coupled receptors form oligomeric assemblies, and many of them exist as homodimers and heterodimers (Terrillon and Bouvier, 2004) . Increasing evidence indicates that oligomerization of G-proteincoupled receptors plays an important role in receptor function. The homodimers of mGluR1 and mGluR5 have been demonstrated previously (Romano et al., 1996; Kunishima et al., 2000) . However, heteromeric mGluRs have not been reported. This phenomenon deserves additional study.
The present study indicates that the IP 3 -mediated intracellular calcium release is necessary and sufficient for downstream NR2B tyr-P associated with hyperalgesia. The application of IP 3 receptor antagonists blocked NR2B tyr-P induced by inflammation in vivo and group I mGluR agonists in vitro, suggesting a critical role of the intracellular calcium release. In contrast, blockage of other potential calcium sources, including NMDA and AMPA/KA receptor channels, and VDCCs was without an effect on NR2B tyr-P. It is rather surprising that in the present study, MK-801, an NMDAR channel blocker, did not prevent NR2B tyr-P after inflammation, although the doses used have been shown to attenuate hyperalgesia (Ren et al., 1992) . This suggests that the NMDAR channel itself does not contribute to the initiation of the increased NR2B tyr-P through a feedforward mechanism. In hippocampus, the increased NR2B tyr-P was observed after the establishment of long-term potentiation and blocked by MK-801 (Rosenblum et al., 1996; Rostas et al., 1996) , suggesting that tyr-P after tetanus is triggered by activation of the NMDAR itself. These apparent contrasting results emphasize the differences in biochemical signaling among different cellular systems. Our MK-801 result suggests that tyr-P of the NMDAR does not depend on the opening status of the NMDAR channel, and MK-801 produces antihyperalgesic effects by acting on an event downstream to initiation of NR2B tyr-P.
The unique contribution of IP 3 receptor-mediated calcium release to NR2B tyr-P raises interesting questions on intracellular calcium signaling and spinal dorsal horn plasticity. Despite multiple calcium sources, our results suggest that the signal pathways upstream to NR2B tyr-P depend on calcium released from the endoplasmic reticulum. Compared with synaptic response involving ionotropic glutamate receptors, the calcium release from the endoplasmic reticulum following mGluR activation exhibits a considerable delay of ϳ200 msec in Purkinje cells in the mouse cerebellum (Takechi et al., 1998) . Nakamura et al. (1999) have shown a difference between the spatial distributions of the NMDAR-mediated calcium changes and mGluR-mediated release, suggesting that these two spatially distinct calcium changes may serve different functions. Compared with calcium release resulting from action potentials, the IP 3 -mediated intracellular calcium release after mGluR activation is much larger and requires repetitive synaptic stimulation (Nakamura et al., 1999) . Because hindpaw inflammation produces a strong primary afferent barrage to dorsal horn neurons followed by mGluR activation, it may satisfy the condition for subsequent "spatially limited" or "functionally compartmentalized" intracellular calcium release that leads to NR2B tyr-P.
Although the communication between mGluR and NMDARs and tyr-P of the NMDAR in the postsynaptic density may be a general mechanism for synaptic modulation, different cellular systems may involve different receptor subunit and distinct second messenger pathways. For example, NR2A tyr-P is upregulated in the rostral ventromedial medulla, a pivotal structure for pain modulation, after inflammation (Turnbach et al., 2003) , whereas the level of NR2A tyr-P was unchanged at the spinal level (Guo et al., 2002a) . Our analysis indicates that both mGluR1 and mGluR5 subtypes of group I mGluRs were required for enhanced NR2B tyr-P and PKC activation, and intracellular calcium release is critical for this effect. In cortical neurons, however, tyr-P of the NMDAR NR2A/B subunits following activation of group I mGluRs was blocked by an mGluR1, but not mGluR5, antagonist, and the activation of PYK2/Src kinase by mGluR agonist DHPG did not appear to depend on PKC but was dependent on Ca 2ϩ -calmodulin (Heidinger et al., 2002) . In addition, the activation of spinal neurokinin 1 receptors also appears to be involved in CFAinduced NR2B tyr-P (Guo et al., 2002a) , suggesting the presence of abundant signaling pathways in the spinal cord.
In summary, these findings demonstrate an mGluR-NMDAR coupling in the spinal dorsal horn involving IP 3 -mediated intracellular calcium release, PKC activation, and Src-induced NR2B tyr-P. These biochemical events are correlated with the development of inflammatory hyperalgesia and may underlie the mechanisms of spinal sensitization. An important implication from the present study is that mGluR facilitates ionotropic synaptic transmission after injury as a mechanism of modulation in the spinal dorsal horn. It is known that tyr-P of the NMDAR results in an increase in NMDAR channel current and Ca 2ϩ influx The NR1 staining showed numerous punctate profiles in the cell membrane, dendrite, and cytoplasm (A 1 ), whereas mGluR5-like immunoreactivity appeared uniformly in the cell membrane and cytoplasm (B 1 ). C 1 shows the same neuron in A 1 and B 1 that is double labeled with anti-NR1 and mGluR5 antibodies. Scale bars: A-C, 0.04 mm; A 1 -C 1 , 0.01 mm. D, Coimmunoprecipitation of NR2B and mGluR5 in the spinal dorsal horn. Spinal dorsal horn tissues were taken from naive rats and inflamed rats at 30 min after injection of CFA into the hindpaw. Proteins were immunoprecipitated with NR2B antibodies and probed with antibodies against NR2B and mGluR5. Note that boiling of the samples before IP eliminated mGluR5, leaving only NR2B that was directly pulled down by NR2B antibodies.
through the channel (Wang and Salter, 1994; Ali and Salter, 2001 ). Thus, one functional consequence of mGluR activation after inflammation is to prime NMDAR for further enhanced hyperexcitability. This mechanism may be a critical initiator for central nociceptive sensitization.
